COMBINATION THERAPY FOR COPD

摘要

Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.

主权项

1. A pharmaceutical composition for use with a pressurized metered dose inhaler, comprising:
(a) glycopyrronium bromide in an amount sufficient to deliver 0.5 to 100 μg per actuation; and (b) formoterol or a salt thereof in an amount sufficient to deliver 1 to 25 μg per actuation; dissolved in an HFA propellant and a co-solvent, wherein said composition comprises an acid in an amount equivalent to 1M HCl in an amount of 0.1 to 0.3 μg/μl of said composition.